Syremis Therapeutics announced its launch and a $165 million Series A financing on December 18, 2025. The company said it would use the funding to advance two investigational neuropsychiatric medicines toward clinical proof of concept. “Best-in-class” was the company’s positioning, not a demonstrated comparative clinical result.
What is Syremis Therapeutics?
Syremis is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric conditions. It was launched by a team that includes co-founder and CEO Elisabeth Kogan. According to the launch announcement, its lead programs, ST-905 and ST-901, were discovered and developed at Clexio Biosciences before being spun out to Syremis.
The announcement described the programs’ mechanisms as emerging and clinically validated. That is the company’s characterization; it does not establish that either investigational drug has proven effective for patients.
Who invested in Syremis’s $165 million Series A?
The December 18, 2025 announcement said Dexcel Pharma and Third Rock Ventures co-led the $165 million round. Bain Capital Life Sciences, GV (Google Ventures), QVT and Pictet also participated. Syremis said the financing would support its pipeline through clinical proof of concept. Read the company’s financing announcement.
#1 Best Overall
What are ST-905 and ST-901?
The two programs differ in their drug targets, intended uses and development stages as reported at Syremis’s December 2025 launch.
| Program | Mechanism | Intended uses | Stage at launch announcement |
|---|---|---|---|
| ST-905 | Dual M1/M4 muscarinic agonist | Schizophrenia and other neuropsychiatric conditions | Phase 1 |
| ST-901 | NMDA antagonist | Major depressive disorder and bipolar depression | IND-enabling studies |
ST-905: muscarinic agonism
Syremis described ST-905 as a dual M1/M4 muscarinic agonist and its lead program. At launch, the company said it was in Phase 1 development for schizophrenia and other neuropsychiatric conditions. The release also mentioned once-daily oral and long-acting injectable formulations as possible development opportunities. Those were not approved products or established dosing regimens.
Rank #2
- Penguin Books
- Ideal for a bookworm
- It's a great choice for a book person
ST-901: NMDA antagonism
ST-901 was described as a novel NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression. The company’s launch announcement forecast Phase 1 entry the following year; that was a forecast made in 2025, not confirmation that the program entered a trial or a current timeline.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What was established at launch—and what is not known now?
The program stages above are announcement-era descriptions, not verified current status. Syremis’s official archive also lists a June 16, 2026 announcement appointing Dr. Aaron Koenig as chief medical officer, but that appointment does not establish whether either drug has advanced since launch. Check Syremis’s announcement archive.
The launch release said more than 20 million people are affected by schizophrenia and other psychotic disorders. That figure is attributable to the company’s December 2025 release; the material reviewed does not identify the original publisher, the year of the underlying estimate or its methodology. It should not be treated as independently verified here.
For personal-finance readers, the announcement is a company-funding milestone rather than an investment recommendation. A large Series A indicates that investors committed capital to develop the company’s pipeline; it does not establish clinical success, regulatory approval, commercial availability or a return for any investor.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
